DOCSLIB.ORG

Correlation Between Clinical Response to Hormone Therapy and Steroid Receptor Content in Prostatic Cancer1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Correlation Between Clinical Response to Hormone Therapy and Steroid Receptor Content in Prostatic Cancer1 [CANCER RESEARCH 38, 4345-4348, November 1978] 0008-5472/78/0038-0000$02.00 Correlation between Clinical Response to Hormone Therapy and Steroid Receptor Content in Prostatic Cancer1 Jan-Àke Gustafsson, Peter Ekman, Marek Snochowski, Anders Zetterberg, Ake Pousette, and Bertil Hogberg Department of Chemistry, Karolinska Institute [J.-A. G., M. S., A. P.], and Department of Urology [P. E.¡and Clinical Pathology Laboratory ¡A.2.], Karolinska Hospital, 104 01 Stockholm 60, Sweden, and Department of Pharmacology, Karolinska Institute and AB LEO Research Laboratories, Helsingborg, Sweden [B. H.] Abstract radical prostatectomy (3); in most other countries the figures are much lower. Hormonal therapy is the dominating form of treatment Thus, hormonal treatment (orchidectomy, estrogen or for prostatic carcinoma. The majority of cases (80%) are progestin administration) is the major tool to control the well controlled for varying times with this regimen. How growth of prostatic cancer. Estrogen therapy is the most ever, thus far there have been no adequate methods to common form of therapy in many countries. However, this predict in which cases hormonal therapy is of less benefit. treatment has many side effects, and the cardiovascular Measurement of cancer tissue content of intracellular complications have gained increasing attention. The mech hormone receptors constitutes progress toward a more anism behind the estrogen activity is still obscure; the individualized therapy in prostatic carcinoma. In this study secretion of luteinizing hormone from the pituitary is de biopsies from 16 cancer patients were taken before ther creased, and, consequently, androgen secretion from the apy was given, and the specimens were analyzed with testes is decreased. A direct estrogenic effect on the regard to content of specific methyltrienolone-binding prostatic cancer still has not been proved. sites. A correlation has been made between receptor As we know that all steroid hormonal activity is mediated content and clinical response to hormonal therapy in each via highly specific intracellular receptor proteins, it should case. Twelve specimens contained measurable amounts be of great importance to measure the amount of intracel of steroid receptors. Of these, one patient died during lular receptors to determine the sensitivity of the cancer irradiation therapy before onset of hormonal treatment. cells to the hormones in question and thus predict the value However, of the remaining 11 patients, 9 responded well of hormone therapy in each individual case. Cases with no to hormones (9/11 ~ 82%). The two receptor-positive measurable receptors might be offered alternative forms of nonresponders had the lowest measurable receptor therapy, i.e., irradiation or cytotoxic drugs, or they might levels in the series. Four specimens contained no detect be considered for radical prostatectomy. It might also be able amounts of receptors. Three of these patients possible to select among different forms of hormonal ther showed no response to therapy (3/4 = 75%) but one was apy, i.e., with estrogens, progestins, other antiandrogens, "false negative." Our data indicate that steroid receptor or glucocorticoids. analysis may become a valuable diagnostic tool in indi In our ongoing research on steroid receptors in prostatic vidualizing the therapy for prostatic cancer. tissue, several cancer specimens have been examined (5, 12). Most of the patients received estrogen treatment fol Introduction lowing removal of the specimen. The aim of this study was to evaluate the existence of any correlation between the The androgen dependence of the prostate gland is well tissue content of hormone receptors and the response of established (6). It has also been observed that neither the tumor to hormonal therapy. cancer nor hyperplasia of the prostate develops in castrates (10). Estrogen treatment is effective in a majority of the cases with prostatic cancer (8), while it has no effect on Materials and Methods benign prostatic hyperplasia. Benign prostatic hyperplasia always develops in the middle or lateral lobes of the pros Patients. Sixteen patients were investigated. The choice tate, whereas cancer almost exclusively starts in the dorsal of therapy was in no case influenced by the results of the lobe (9). The rare cases with periurethral cancers are hormone receptor analysis. All patients were randomized claimed to be nonresponsive to hormonal treatment (4). and received either polyestradiol phosphate (Estradurin), Radical operations for prostatic cancer are seldom per 80 to 160 mg/month, in combination with ethynyl estradiol formed, partly because many patients suffering from the (Etivex), 100 to 150 ¿¿g/day,orestramustine phosphate disease are poor risks, but also because the tumor has (Estracyt),420 to 840 mg/day. Two of the patients with often spread outside the capsule when first diagnosed. In poorly differentiated tumors had no demonstrable métas the U.S., only 7% of all prostatic cancers are submitted for tases and were therefore started on irradiation therapy according to our general principles for treatment of these cases. One to 2 months after the cessation of irradiation 1 A preliminary report. Presented at the John E. Fogarty International therapy, hormonal therapy was initiated. Patient 10 was Center Conference on Hormones and Cancer, March 29 to 31, 1978, Bethesda, Md. Supported by grants from Riksföreningen mot Cancer, LEO orchidectomized bilaterally at the time of the biopsy and Research Foundation, Svenska Läkaresällskapet, and Karolinska Institute. was also given Estracyt therapy. NOVEMBER 1978 4345 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 1978 American Association for Cancer Research. J.-Â. Gustafsson et al Clinical response was evaluated by the following param tion therapy before initiation of hormonal treatment. Nine of eters: (a) decreased palpable size of the gland, withdrawal the remaining 11 patients showed a good response to of an indwelling catheter, and improved micturition, (b) estrogen treatment. The 2 receptor-positive nonresponders relief of pain and/or measurable decrease of known métas had the lowest measured amounts of receptor in the series tases; (c) normalization or marked decrease of elevated (Table 1). It is possible that this indicates that a minimum acid phosphatase levels; and (d) squamous cell metaplasia amount of receptor protein is required if a response to as demonstrated by fine-needle aspiration biopsies. hormonal therapy is to be expected. The patients were regularly and carefully checked; the Four specimens lacked measurable amounts of receptor examining physician was unaware of the results of the protein. Three of them did not respond to hormonal treat receptor analyses when judging whether or not improve ment, but one had a good remission from estrogen therapy ment had occurred. Improvement was usually visible within and should be regarded as "false receptor-negative." 3 months after the start of therapy. The relative correlation between steroid receptor content Tumor Specimens. All of the cancer specimens were and response to hormonal treatment in our series was removed via perineal biopsy. The biopsy was performed approximately 80% (9/11 * 82%; 3/4 = 75%). before initiation of any therapy. We used the needle de signed by Veenema in 1953 (13). From each patient 3 or 4 Discussion biopsies were taken, yielding a total specimen weight of 0.05 to 0.20 g. From each biopsy parts were taken for Practical application of the concept of steroid hormone histological examination. A careful histological analysis of receptors has already been achieved in the treatment of each specimen was undertaken since it is almost impossible breast cancer. A good correlation exists between the con to obtain pure adenocarcinomatous tissue with needle tent of estrogen receptors in the cancer tissue and the biopsy. There is usually some contamination, mainly with response to endocrine treatment (7). The conditions are muscle cells but also with fibroblasts. However, this con thought to be similar for prostatic cancer; in fact, the tamination does not seem to disturb the analyses. The clinical importance of steroid receptor measurements may content of steroid receptors in muscle cells is negligible be even greater in this disease, inasmuch as hormonal (unpublished observations). All biopsies containing ele treatment is the dominating form of therapy in prostatic ments of normal and hyperplastic tissue were excluded carcinoma. from the study. Histologically, cancer of the prostate is often quite heter The biopsies were frozen to -70° within 1 hr. At this ogeneous with parts of high degree of differentiation mixed temperature the receptors seemed to be unaffected for at with areas of moderate to low differentiation. It is quite least 6 months. conceivable that different parts of the same tumor may have Receptor Quantitäten.The methodology used for recep different degrees of hormone dependence, possibly as a tor quantitation has been described in detail in a previous result of a multiclonal cancer debut. paper (12). Because of the minor amount of available tissue The receptor assay used in the present investigation is in each case, we were forced to limit our analysis to the use relatively tissue-consuming. The majority of the specimens of one steroid ligand. We have focused our interest on the have been taken from advanced cancers since biopsies tissue content of specific high-affinity, low-capacity binding from
Load more

Recommended publications
  • CANVAS Trial)
    Effectiveness research with Real World Data to support FDA’s regulatory decision making 1. RCT Details This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases. 1.1 Title Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS trial) 1.2 Intended aim(s) To compare canagliflozin to placebo on cardiovascular (CV) events including CV death, heart attack, and stroke in patients with type 2 diabetes mellitus (T2DM), whose diabetes is not well controlled at the beginning of the study and who have a history of CV events or have a high risk for CV events. 1.3 Primary endpoint for replication and RCT finding Major Adverse Cardiovascular Events, Including CV Death, Nonfatal Myocardial Infarction (MI), and Nonfatal Stroke 1.4 Required power for primary endpoint and noninferiority margin (if applicable) With 688 cardiovascular safety events recorded across the trials, there would be at least 90% power, at an alpha level of 0.05, to exclude an upper margin of the 95% confidence interval for the hazard ratio of 1.3. 1.5 Primary trial estimate targeted for replication HR = 0.86 (95% CI 0.75–0.97) comparing canagliflozin to placebo (Neal et al., 2017) 2. Person responsible for implementation of replication in Aetion Ajinkya Pawar, Ph.D. implemented the study design in the Aetion Evidence Platform. S/he is not responsible for the validity of the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform.
    [Show full text]
  • A Pharmaceutical Product for Hormone Replacement Therapy Comprising Tibolone Or a Derivative Thereof and Estradiol Or a Derivative Thereof
    Europäisches Patentamt *EP001522306A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 306 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/567, A61K 31/565, 13.04.2005 Bulletin 2005/15 A61P 15/12 (21) Application number: 03103726.0 (22) Date of filing: 08.10.2003 (84) Designated Contracting States: • Perez, Francisco AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08970 Sant Joan Despi (Barcelona) (ES) HU IE IT LI LU MC NL PT RO SE SI SK TR • Banado M., Carlos Designated Extension States: 28033 Madrid (ES) AL LT LV MK (74) Representative: Markvardsen, Peter et al (71) Applicant: Liconsa, Liberacion Controlada de Markvardsen Patents, Sustancias Activas, S.A. Patent Department, 08028 Barcelona (ES) P.O. Box 114, Favrholmvaenget 40 (72) Inventors: 3400 Hilleroed (DK) • Palacios, Santiago 28001 Madrid (ES) (54) A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof (57) A pharmaceutical product comprising an effec- arate or sequential use in a method for hormone re- tive amount of tibolone or derivative thereof, an effective placement therapy or prevention of hypoestrogenism amount of estradiol or derivative thereof and a pharma- associated clinical symptoms in a human person, in par- ceutically acceptable carrier, wherein the product is pro- ticular wherein the human is a postmenopausal woman. vided as a combined preparation for simultaneous, sep- EP 1 522 306 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 1 522 306 A1 2 Description [0008] The review article of Journal of Steroid Bio- chemistry and Molecular Biology (2001), 76(1-5), FIELD OF THE INVENTION: 231-238 provides a review of some of these compara- tive studies.
    [Show full text]
  • Eligibility Regulations for Transgender Athletes
    ELIGIBILITY REGULATIONS FOR TRANSGENDER ATHLETES In the case of confidential queries regarding cases affected by these Transgender Regulations, please contact: WT Medical Manager (email: [email protected]) Table of Contents 1. Introduction ....................................................................................................................... 1 2. Application ........................................................................................................................ 3 3. Eligibility Conditions For Transgender Athletes ................................................................... 5 3a. Eligibility conditions for Transgender male athletes .......................................................... 5 3b. Eligibility conditions for Transgender female athletes ....................................................... 5 3c. Provisions applicable to all Transgender athletes .............................................................. 5 4. Assessment by the Expert Panel ......................................................................................... 7 5. Monitoring/Investigating Compliance ................................................................................ 9 6. Disciplinary Proceedings .................................................................................................... 11 7. Dispute Resolution ............................................................................................................ 12 8. Confidentiality .................................................................................................................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Cumulative Cross Index to Iarc Monographs
    PERSONAL HABITS AND INDOOR COMBUSTIONS volume 100 e A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 29 September-6 October 2009 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS The volume, page and year of publication are given. References to corrigenda are given in parentheses. A A-α-C .............................................................40, 245 (1986); Suppl. 7, 56 (1987) Acenaphthene ........................................................................92, 35 (2010) Acepyrene ............................................................................92, 35 (2010) Acetaldehyde ........................36, 101 (1985) (corr. 42, 263); Suppl. 7, 77 (1987); 71, 319 (1999) Acetaldehyde associated with the consumption of alcoholic beverages ..............100E, 377 (2012) Acetaldehyde formylmethylhydrazone (see Gyromitrin) Acetamide .................................... 7, 197 (1974); Suppl. 7, 56, 389 (1987); 71, 1211 (1999) Acetaminophen (see Paracetamol) Aciclovir ..............................................................................76, 47 (2000) Acid mists (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists and vapours from) Acridine orange ...................................................16, 145 (1978); Suppl. 7, 56 (1987) Acriflavinium chloride ..............................................13,
    [Show full text]
  • Estradiol for the Mitigation of Adverse Effects of Androgen Deprivation Therapy
    248 N Russell et al. Estradiol and androgen 24:8 R297–R313 Review deprivation therapy Estradiol for the mitigation of adverse effects of androgen deprivation therapy Nicholas Russell1,2, Ada Cheung1,2 and Mathis Grossmann1,2 Correspondence should be addressed 1 Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia to N Russell 2 Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia Email [email protected] Abstract Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. Key Words Conventional endocrine treatment for PCa leads to global sex steroid deprivation. f endocrine therapy The ensuing severe hypogonadism is associated with well-documented adverse effects. f prostate Recently, it has become apparent that many of the biological actions attributed to f estrogen androgens in men are in fact not direct, but mediated by estradiol. Available evidence f androgen supports a primary role for estradiol in vasomotor stability, skeletal maturation and f testosterone maintenance, and prevention of fat accumulation. Hence there has been interest in revisiting estradiol as a treatment for PCa. Potential roles for estradiol could be in lieu of conventional androgen deprivation therapy or as low-dose add-back treatment while continuing androgen deprivation therapy. These strategies may limit some of the side Endocrine-Related Cancer Endocrine-Related effects associated with conventional androgen deprivation therapy. However, although available data are reassuring, the potential for cardiovascular risk and pro-carcinogenic Endocrine-Related Cancer effects on PCa via estrogen receptor signalling must be considered. (2017) 24, R297–R313 Introduction Prostate cancer (PCa) is the second most commonly and extragonadal androgen synthesis inhibitors.
    [Show full text]
  • Vastly Extended Drug Release from Poly(Pro-17β-Estradiol)
    ARTICLE https://doi.org/10.1038/s41467-019-12835-w OPEN Vastly extended drug release from poly(pro-17β- estradiol) materials facilitates in vitro neurotrophism and neuroprotection Anthony R. D’Amato 1, Devan L. Puhl 1,3, Samuel A.T. Ellman2,3, Bailey Balouch1, Ryan J. Gilbert 1*& Edmund F. Palermo 2* 1234567890():,; Central nervous system (CNS) injuries persist for years, and currently there are no ther- apeutics that can address the complex injury cascade that develops over this time-scale. 17β- estradiol (E2) has broad tropism within the CNS, targeting and inducing beneficial phenotypic changes in myriad cells following injury. To address the unmet need for vastly prolonged E2 release, we report first-generation poly(pro-E2) biomaterial scaffolds that release E2 at nanomolar concentrations over the course of 1–10 years via slow hydrolysis in vitro. As a result of their finely tuned properties, these scaffolds demonstrate the ability to promote and guide neurite extension ex vivo and protect neurons from oxidative stress in vitro. The design and testing of these materials reported herein demonstrate the first step towards next- generation implantable biomaterials with prolonged release and excellent regenerative potential. 1 Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th St., Troy, NY 12180, USA. 2 Materials Science and Engineering, Rensselaer Polytechnic Institute, 110 8th St., Troy, NY 12180, USA. 3These authors contributed equally: Devan L. Puhl, Samuel A.T. Ellman. *email: [email protected]; [email protected] NATURE COMMUNICATIONS | (2019) 10:4830 | https://doi.org/10.1038/s41467-019-12835-w | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12835-w njuries to the Central Nervous System (CNS), including Spinal thereby enabling faster regeneration along the orientation of the ICord Injury (SCI) and Traumatic Brian Injury (TBI), present fibers33.
    [Show full text]
  • Controversies in the Management of Advanced Prostate Cancer
    British Journal of Cancer (1999) 79(1), 146–155 © 1999 Cancer Research Campaign Controversies in the management of advanced prostate cancer CJ Tyrrell Oncology Research Unit, Derriford Hospital, Plymouth, UK Summary For advanced prostate cancer, the main hormone treatment against which other treatments are assessed is surgical castration. It is simple, safe and effective, however it is not acceptable to all patients. Medical castration by means of luteinizing hormone-releasing hormone (LH-RH) analogues such as goserelin acetate provides an alternative to surgical castration. Diethylstilboestrol, previously the only non-surgical alternative to orchidectomy, is no longer routinely used. Castration reduces serum testosterone by around 90%, but does not affect androgen biosynthesis in the adrenal glands. Addition of an anti-androgen to medical or surgical castration blocks the effect of remaining testosterone on prostate cells and is termed combined androgen blockade (CAB). CAB has now been compared with castration alone (medical and surgical) in numerous clinical trials. Some trials show advantage of CAB over castration, whereas others report no significant difference. The author favours the view that CAB has an advantage over castration. No study has reported that CAB is less effective than castration. Of the anti-androgens which are available for use in CAB, bicalutamide may be associated with a lower incidence of side-effects compared with the other non-steroidal anti-androgens and, in common with nilutamide, has the advantage of once-daily dosing. Only one study has compared anti-androgens within CAB: bicalutamide plus LH-RH analogue and flutamide plus LH-RH analogue. At 160- week follow-up, the groups were equivalent in terms of survival and time to progression.
    [Show full text]
  • Parenteral Estrogen Versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No
    Scandinavian Journal of Urology and Nephrology ISSN: 0036-5599 (Print) 1651-2065 (Online) Journal homepage: https://www.tandfonline.com/loi/isju19 Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5 Per Olov Hedlund, Martti Ala-Opas, Einar Brekkan, Jan Erik Damber, Lena Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Åke Pousette, Finn Rasmussen, Jaakko Salo, Sigmund Vaage & Eberhard Varenhorst To cite this article: Per Olov Hedlund, Martti Ala-Opas, Einar Brekkan, Jan Erik Damber, Lena Damber, Inger Hagerman, Svein Haukaas, Peter Henriksson, Peter Iversen, Åke Pousette, Finn Rasmussen, Jaakko Salo, Sigmund Vaage & Eberhard Varenhorst (2002) Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5, Scandinavian Journal of Urology and Nephrology, 36:6, 405-413, DOI: 10.1080/003655902762467549 To link to this article: https://doi.org/10.1080/003655902762467549 Published online: 09 Jul 2009. Submit your article to this journal Article views: 72 Citing articles: 33 View citing articles Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=isju20 ORIGINAL ARTICLE Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer ScandinavianProstatic Cancer Group(SPCG) Study No. 5 Per Olov Hedlund,
    [Show full text]
  • Centre for Reviews and Dissemination Parenteral Oestrogens for Prostate
    Centre for Reviews and Dissemination A Systematic Review of Parenteral Oestrogens for Prostate Cancer Parenteral Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response 33 Promoting the use of research based knowledge REPORT 33 CRD Parenteral oestrogens for prostate cancer: A systematic review of clinical effectiveness and dose response Michael Emmans Dean2 Gill Norman1 Zoé Hodges6 Gill Ritchie3 Kate Light1 Alison Eastwood1 Ruth Langley4 Matthew Sydes4 Mahesh Parmar4 Paul Abel5 1 Centre for Reviews and Dissemination, University of York, York YO10 5DD 2 Department of Health Sciences, University of York, York YO10 5DD 3National Collaborating Centre for Primary Care, Frazer House, 32-38 Leman Street, London, E1 8EW 4MRC Clinical Trials Unit, 222 Euston Road, London 5Imperial College, London, W12 0NN 6 Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, WC1B 3RE September 2006 © 2006 Centre for Reviews and Dissemination, University of York ISBN 1 900640 37 6 This report can be ordered from: Publications Office, Centre for Reviews and Dissemination, University of York, York YO10 5DD. Telephone 01904 321458; Facsimile: 01904 321035: email: [email protected] Price £12.50 The Centre for Reviews and Dissemination is funded by the NHS Executive and the Health Departments of Wales and Northern Ireland. The views expressed in this publication are those of the authors and not necessarily those of the NHS Executive or the Health Departments of Wales or Northern Ireland. Printed by York Publishing Services Ltd. ii CENTRE FOR REVIEWS AND DISSEMINATION The Centre for Reviews and Dissemination (CRD) is a facility commissioned by the NHS Research and Development Division.
    [Show full text]
  • Cardiovascular Toxicities of Systemic Treatments of Prostate Cancer
    CORRESPONDENCE LINK TO ORIGINAL ARTICLE LINK TO AUTHOR’S REPLY knowledge to participate in choosing favoured therapies. Sharing decision mak- Cardiovascular toxicities of systemic ing will offer opportunities for patients, enabling them, together with their families treatments of prostate cancer: and friends, to engage with personalized medicine, but this process requires thorough oestrogen to the rescue? acquisition of comprehensive, up-to-date, relevant background data. Syed Imran A. Shah, Hannah C. P. Wilson & Paul D. Abel Syed Imran A. Shah is at the Biochemistry Department at Central Park Medical College, Central Park Housing Scheme, 31 km Ferozepur Road, Kahna Nau, Lahore, In their Review (Cardiovascular toxicities By the early 1990s, reports of paren- Punjab, Pakistan. of systemic treatments of prostate cancer. teral oestrogen administration for prostate Hannah C. P. Wilson is at Imperial NHS Trust, 1 Nat. Rev. Urol. 14, 230–243 (2017)) Veccia cancer (injection or skin patch) had been The Bays, South Wharf Road, St Mary’s Hospital, et al. offer useful insight into current encouraging. A Scandinavian research team London W2 1NY. knowledge concerning cardiovascular com- recruited 915 men into a two-arm study of Paul D. Abel is at South Kensington Campus, plications of oral oestrogen, androgen dep- luteinising-hormone-releasing hormone London, SW7 2AZ, UK . rivation therapy (ADT), and prostate cancer. (LHRH) agonist plus antiandrogens ver- Correspondence to: S.I.A.S. However, we do not share the confidence and sus intramuscular polyestradiol phosphate [email protected] strength of their assertion that “oestrogens (a synthetic oestrogen). Overall prostate can- doi:10.1038/nrurol.2017.126 are no longer used in patients with prostate cer mortality was equivalent between groups, Published online 8 Aug 2017 cancer owing to the severity of their adverse but cardiovascular morbidity was either events, which include thromboembolic and not reported or slightly increased in the 1.
    [Show full text]
  • Parenteral Oestrogen in the Treatment of Prostate Cancer: a Systematic Review
    British Journal of Cancer (2008) 98, 697 – 707 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $30.00 www.bjcancer.com Parenteral oestrogen in the treatment of prostate cancer: a systematic review G Norman1, ME Dean1, RE Langley2, ZC Hodges1, G Ritchie1, MKB Parmar2, MR Sydes2, P Abel3 *,1 and AJ Eastwood 1 2 Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK; Cancer Group, MRC Clinical Trials Unit, 222 Euston Road, London 3 NW1 2DA, UK; Hammersmith Campus, Department of Surgery, Imperial College Faculty of Medicine, London W12 0NN, UK The objectives of this study were to assess the effectiveness and safety of parenteral oestrogen in the treatment of prostate cancer, Clinical Studies and to examine any dose relationship. A systematic review was undertaken. Electronic databases, published paper and internet resources were searched to locate published and unpublished studies with no restriction by language or publication date. Studies included were randomised controlled trials of parenteral oestrogen in patients with prostate cancer; other study designs were also included to examine dose–response. Study selection, appraisal, data extraction and quality assessment were performed by one reviewer and independently checked by another. Twenty trials were included in the review. The trials differed with regard to the included patients, formulation and dose of parenteral oestrogen, comparator used, outcome measures reported and the duration of follow-up. The results provide no evidence to suggest that parenteral oestrogen, in doses sufficient to produce castrate levels of testosterone, is less effective than luteinising hormone-releasing hormone (LHRH) or orchidectomy in controlling prostate cancer, or that it is consistently associated with an increase in cardiovascular mortality.
    [Show full text]